Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis.
Menopause. 2023 Aug 1;30(8):855-866. doi: 10.1097/GME.0000000000002211. Epub 2023 Jun 27.
Menopause. 2023.
PMID: 37369079
Free PMC article.
No cases of endometrial carcinoma or hyperplasia were observed in ospemifene trials, nor polyps with atypical hyperplasia or cancer after up to 52 weeks of treatment. ...Efficacy and safety outcomes with ospemifene are similar to other VVA therapies in North America …
No cases of endometrial carcinoma or hyperplasia were observed in ospemifene trials, nor polyps with atypical hyperplasia or cancer a …
'HPV vulvitis' revisited: frequent and persistent detection of novel epidermodysplasia verruciformis-associated HPV genotypes.
Lin MT, Rohwedder A, Mysliborski J, Leopold K, Wilson VL, Carlson JA.
Lin MT, et al.
J Cutan Pathol. 2008 Mar;35(3):259-72. doi: 10.1111/j.1600-0560.2007.00805.x.
J Cutan Pathol. 2008.
PMID: 18251739
METHODS: Using degenerate and type specific primers for cutaneous (CU), GM and epidermodysplasia verruciformis (EV) HPV types, the prevalence of specific HPV types was investigated in biopsy specimens from 19 women with 'HPV vulvitis', seven with asymptomatic vulvar squamous papi …
METHODS: Using degenerate and type specific primers for cutaneous (CU), GM and epidermodysplasia verruciformis (EV) HPV types, the prevalenc …
Item in Clipboard
Cite
Cite